Premium
Effect of Pharmaceutical Care on Optimum Colestipol Treatment in Elderly Hypercholesterolemic Veterans
Author(s) -
Konzem Sherri L.,
Gray David R.,
Kashyap Moti L.
Publication year - 1997
Publication title -
pharmacotherapy: the journal of human pharmacology and drug therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.227
H-Index - 109
eISSN - 1875-9114
pISSN - 0277-0008
DOI - 10.1002/j.1875-9114.1997.tb03068.x
Subject(s) - medicine , pharmaceutical care , pharmacist , drug , nursing , pharmacology , pharmacy
We conducted a prospective trial to determine whether a formal, integrated pharmaceutical care plan can enhance patient acceptance and compliance with colestipol therapy and improve outcomes. Forty patients with hypercholesterolemia were equally divided and assigned to either a usual care or pharmaceutical care group. In the pharmaceutical care group compared with the usual care group, after 52 weeks, colestipol therapy resulted in a greater reduction in total cholesterol (12.5% vs 7.3%), low‐density lipoprotein cholesterol (LDL‐C; 16% vs 9.4%), and LDL‐C:high‐density lipoprotein cholesterol (HDL‐C) ratio (24.4% vs 12.2%, p<0.05). The percentage of patients who achieved their LDL‐C goal at week 52 was much greater in the pharmaceutical care group (29.4%) than in the usual care group (5.0%, p<0.05). Comanagement by a physician and a pharmacist of hypercholesterolemic veterans treated with colestipol can enhance patient acceptance of the drug, LDL‐C reduction, and achievement of therapeutic goals.